Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Flezurafenib · JZP-815

Small molecule · Inhibitor of B-Raf, A-Raf and C-Raf (RAF1) · developed by Jazz Pharmaceuticals

Phase 1 Most advanced trial

JAZZ Developer

1 Registered trials

What is Flezurafenib?

Flezurafenib is an orally bioavailable inhibitor of Raf family kinases (A-Raf, B-Raf, C-Raf), including wild-type and mutated forms. It prevents Raf-mediated signal transduction and inhibits the Ras-MAPK pathway, reducing tumor cell proliferation. It is studied in melanoma, non-small cell lung cancer, colorectal cancer, and anaplastic thyroid cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: JZP-815
Drug type: Small molecule
Targets: B-Raf, A-Raf, C-Raf (RAF1)
Mechanism: Inhibitor of B-Raf, A-Raf and C-Raf (RAF1)
Pathways: MAPK/ERK, Ras signaling
Therapy area: Oncology
Developer: Jazz Pharmaceuticals (JAZZ)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1
UNII: P26TTM6U27

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05557045	Phase 1	Advanced Cancer	Active not recruiting	JAZZ

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced CancerAnaplastic Thyroid Cancer (ATC)Colorectal Cancer (CRC)MelanomaMetastatic CancerNon-small Cell Lung Cancer (NSCLC)Solid Tumor

Other drugs acting on BRAF / ARAF / RAF1

Tagarafdeg Phase 1

More from Jazz Pharmaceuticals

Asparaginase Erwinia chrysanthemi FDA approved Calcium, Magnesium, Potassium, And Sodium Oxybates FDA approved Daunorubicin And Cytarabine Liposome FDA approved Defibrotide FDA approved Lurbinectedin FDA approved Zanidatamab FDA approved CBD-OS Phase 3 JZP269 Phase 1 JZP926 Phase 2/3 Nabiximols Phase 2 ONC206 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the JAZZ page.

Follow JAZZ, the company behind Flezurafenib

See JAZZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

JAZZ catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z